Claims for Patent: 9,427,402

Summary for Patent: 9,427,402

Title:	Preparation for improving solubility of poorly soluble drug
Abstract:	The present invention relates to solubility improving preparation for enhancing the oral absorption of a poorly soluble drug, which is comprising (A) and (B); (A) a granulated substance which comprises (i) a poorly soluble drug having an acidic group in the molecule, (ii) an alkaline agent, (iii) a surfactant, and this granulated substance dose not substantially contain a disintegrator, (B) a disintegrator existing only in the external of the granulated substance.
Inventor(s):	Sakuma; Satoshi (Amagasaki, JP), Ueda; Hiroshi (Toyonaka, JP), Mashimo; Akira (Amagasaki, JP), Murazato; Hiroshi (Osaka, JP)
Assignee:	Shionogi & Co. Ltd. (Osaka, JP)
Application Number:	13/825,552
Patent Claims:	1. A solid preparation comprising: (A) a granulated substance comprising (i) a poorly soluble drug having a carboxyl group in the molecule, wherein the poorly soluble drug is an optically active compound represented by Formula (I): ##STR00008## wherein, R.sup.1 is chosen from halogen atoms and C.sub.1-C.sub.3 alkyloxy groups; R.sup.2 is chosen from C.sub.1-C.sub.8 alkyl groups; R.sup.3 is chosen from C.sub.1-C.sub.8 alkyl groups; R.sup.4 and R.sup.5 are each independently chosen from a fluorine atom and a chlorine atom; R.sup.6 is chosen from C.sub.1-C.sub.3 alkyl groups and C.sub.1-C.sub.3 alkyl oxy groups; and the carbon atom with "*" attached to it is an asymmetric carbon, its pharmaceutically acceptable salt, or solvate thereof (ii) an alkaline agent, wherein the alkaline agent is chosen from magnesium oxide, magnesium hydroxide, hydroxylation alumina magnesium, synthetic hydrotalcite, calcium silicate and mixtures thereof, wherein the alkaline agent is present in an amount of 0.5 to 30 weight % based on the weight of the granulated substance, (iii) a surfactant, wherein the surfactant is chosen from sodium lauryl sulfate, sucrose fatty acid ester and polyoxyethylene polyoxypropylene glycol, wherein the surfactant is present in an amount of 0.2 to 50 weight % based on the weight of the granulated substance, wherein the granulated substance does not substantially contain a disintegrator, and (B) a disintegrator external to the granulated substance. 2. The solid preparation according to claim 1, wherein the poorly soluble drug is (S)-(E)-3-(2,6-dichloro-4-{4-[3-(1-hexyloxyethyl)-2-methyloxyphen- yl]thiazole 2-yl carbamoyl}phenyl)-2-methylacrylic acid, its pharmaceutically acceptable salt, or solvate thereof. 3. The solid preparation according to claim 1, wherein the alkaline agent is magnesium oxide and/or magnesium hydroxide. 4. The solid preparation according to claim 3, wherein 0.5 to 30 weight % of magnesium oxide and/or 0.5 to 30 weight % of magnesium hydroxide are contained as alkaline agents based on the said granulated substance. 5. The solid preparation according to claim 1, wherein the surfactant is an ionic surfactant. 6. The solid preparation according to claim 5, wherein the ionic surfactant is a sulfuric acid ester salt. 7. The solid preparation according to claim 6, wherein the sulfuric acid ester salt is a sodium lauryl sulfate. 8. The solid preparation according to claim 1, wherein the disintegrator is chosen from cellulosic derivative, polyvinyl pyrrolidone derivative and starch derivative. 9. The solid preparation according to claim 8, wherein the disintegrator is chosen from a low substituted hydroxypropyl cellulose, carmellose calcium, crospovidone, and carboxymethyl starch sodium. 10. The solid preparation according to claim 9, wherein carmellose calcium is present in an amount of 0.2 to 30 weight % based on the weight of the solid preparation. 11. The solid preparation according to claim 10, wherein carmellose calcium is present in an amount of 3 to 7 weight % based on the weight of the solid preparation. 12. The solid preparation according to claim 1, wherein the granulated substance contains hydroxypropyl cellulose. 13. The solid preparation according to claim 12, wherein hydroxypropyl cellulose is present in an amount of 0.1 to 20 weight % based on the weight of the granulated substance. 14. The solid preparation according to claim 1, wherein magnesium oxide is present in an amount of 0.5 to 30 weight %, magnesium hydroxide is present in an amount of 0.5 to 30 weight %, sodium lauryl sulfate is present in an amount of 0.2 to 50 weight %, and hydroxypropyl cellulose is present in an amount of 0.1 to 20 weight % based on the weight of the granulated substance, and wherein the disintegrator is carmellose calcium present in an amount of 0.2 to 30 weight % based on the weight of the solid preparation. 15. The solid preparation according to claim 14, wherein the poorly soluble drug is (S)-(E)-3-(2,6-dichloro-4-{4-[3-(1-hexyloxyethyl)-2-methyloxyphenyl]thiaz- ole 2-yl carbamoyl}phenyl)-2-methylacrylic acid, its pharmaceutically acceptable salt, or solvate thereof. 16. The solid preparation according to claim 14, wherein carmellose calcium is present in an amount of 3 to 7 weight % based on the weight of the solid preparation. 17. The solid preparation according to claim 1, wherein the solid preparation form is tablet or capsule. 18. The solid preparation according to claim 17, wherein the solid preparation form is tablet. 19. A process for producing the solid preparation according to claim 1 containing: (A) mixing (i) the poorly soluble drug having an acidic group in the molecule of claim 1, (ii) an alkaline agent, (iii) a surfactant, and granulating the mixture, (B) mixing the granulated substance prepared in (A) with a disintegrator, and (C) obtaining the solid preparation according to claim 1. 20. A method for improving the solubility of the poorly soluble drug having an acidic group in the molecule according to claim 1, wherein the method contains (A) mixing (i) the poorly soluble drug having an acidic group in the molecule, (ii) an alkaline agent, (iii) a surfactant, and granulating the mixture, (B) mixing the granulated substance prepared in (A) with a disintegrator, and (C) obtaining the solid preparation according to claim 1, wherein after mixing (B), the solubility of the poorly soluble drug according to claim 1 has improved solubility.